ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
会议论文

A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer

Ding, K.; Liu, Y.; Song, Y.; Xu, D.; Li, J.; Wang, J.; Chen, X.; Lin, R.; Jiang, Y.; Zhang, Y.; Zhang, W.; Cheng, Y.; Wu, X.; Yuan, Y.汕头大学; 江南大学; 哈尔滨医科大学; 浙江大学; 1
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)2022-9DOI: 10.1016/j.annonc.2022.07.1862
10阅读
引用收藏
分享
相关
加载中…
  • Update of a phase II, multicenter clinical trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
    Yan, Jin; Han, Yunwei; Zhang, Li; Jin, Yongdong; Sun, HaoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
  • A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
    Wang, F.; Xiao, J.; Zhang, Y.; Yuan, X.; He, M.; Fang, W.; Zhang, Y.; Wang, W.; Hu, X.; Ma, Z.; Yao, Y.; Zhuang, Z.; Zhou, F.; Ying, J.; Yuan, Y.; Zou, Q.; Guo, Z.; Wu, X.; Jin, Y.; Mai, Z.; Guo, Y.; Xu, R.ESMO 24th World Congress on Gastrointestinal Cancer, Barcelona, SPAIN, 2022-06-29 To 2022.
  • Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
    Yan, Jin; Han, Yunwei; Zhang, Li; Jin, Yongdong; Sun, HaoGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.
查看全部 →

会议信息

会议名称
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)
会议日期
2022-09-09 至 2022-09-13
论文集名
ANNALS OF ONCOLOGY
发表日期
2022-09
起止页码
S736-S736
DOI
10.1016/j.annonc.2022.07.1862
资助标注
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
收录
ISTP · SCIE

作者

  • D

    Ding, K. (第一作者)

    1 · 2 · zhejiang univ

  • L

    Liu, Y.

    1 · 2 · zhejiang univ

查看全部 14 位作者收起作者
  • S

    Song, Y.

    1 · 2 · zhejiang univ

  • X

    Xu, D.

    1 · 2 · zhejiang univ

  • L

    Li, J.

    1 · 2 · zhejiang univ

  • W

    Wang, J.

    jining med coll

  • C

    Chen, X.

  • L

    Lin, R.

    fujian prov tumor hosp

  • J

    Jiang, Y.

    shantou univ

  • Z

    Zhang, Y.

    harbin med univ

  • Z

    Zhang, W.

    gansu prov people hosp

  • C

    Cheng, Y.

  • W

    Wu, X.

    jiangnan univ

  • Y

    Yuan, Y.

    1 · 2 · zhejiang univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417